Literature DB >> 16964435

The effect of stromal cell-derived factor 1 (SDF1/CXCL12) genetic polymorphism on HIV-1 disease progression.

Edna Maria Vissoci Reiche1, Maria Angelica Ehara Watanabe, Ana Maria Bonametti, Helena Kaminami Morimoto, Arilson Akira Morimoto, Susana Lilian Wiechmann, Jose Wander Breganó, Tiemi Matsuo, Fernando Vissoci Reiche, Helen Cristina Miranda, Karen Brajão Oliveira, Ingridt Hildegard Vogler, Alexandra Regina Siscar.   

Abstract

The human immunodeficiency virus type 1 (HIV-1) epidemic is increasing in Brazil, and little information has been reported about the genetic host factors related to HIV-1 infection in the Brazilian population. A polymorphism in the conserved 3' untranslated region of the stromal cell-derived factor 1 (SDF1/CXCL12) gene has been related either to resistance to HIV-1 infection and delayed progression to AIDS or to rapid disease progression and death. A longitudinal study was conducted to evaluate the association of the SDF1 polymorphism and the progression of HIV-1 infection in 161 asymptomatic patients infected with HIV-1 (ASYMPT) and 617 patients with AIDS (SYMPT) from Londrina and the surrounding region, southern Brazil. The endpoints used were the development of AIDS, death, and the slopes of the CD4+ T cell counts and HIV-1 RNA plasma levels. Among the 161 ASYMPT patients, all of the 7 patients (4.3%) homozygous for the mutation remained asymptomatic (p=0.1906); 6 of them had not initiated antiretroviral therapy. Among the 617 patients with AIDS, 40 (6.5%) progressed to death. Of these, 33/388 (8.5%) did not have the SDF1-3'A allele, 6/196 (3.1%) were heterozygous and 1/33 (3.0%) was homozygous for the SDF1-3'A allele (p=0.029). The SDF1 genotypes were not associated with the surrogate markers of HIV-1 disease progression such as the CD4+ T cell decline and plasma HIV-1 RNA levels. The results observed in this study support the hypothesis that the mutation of SDF1-3'A could have a possible late-stage protective effect on HIV-1 disease progression in the Brazilian population.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16964435

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  3 in total

1.  Genetic variation in CXCL12 and risk of cervical carcinoma: a population-based case-control study.

Authors:  S N Maley; S M Schwartz; L G Johnson; M Malkki; Q Du; J R Daling; S S Li; L P Zhao; E W Petersdorf; M M Madeleine
Journal:  Int J Immunogenet       Date:  2009-09-24       Impact factor: 1.466

2.  CXCL12 rs1801157 polymorphism in patients with breast cancer, Hodgkin's lymphoma, and non-Hodgkin's lymphoma.

Authors:  Karen Brajão de Oliveira; Julie Massayo Maeda Oda; Julio Cesar Voltarelli; Thiago Franco Nasser; Mario Augusto Ono; Thiago Cezar Fujita; Tiemi Matsuo; Maria Angelica Ehara Watanabe
Journal:  J Clin Lab Anal       Date:  2009       Impact factor: 2.352

Review 3.  The chemokine network. II. On how polymorphisms and alternative splicing increase the number of molecular species and configure intricate patterns of disease susceptibility.

Authors:  R Colobran; R Pujol-Borrell; M P Armengol; M Juan
Journal:  Clin Exp Immunol       Date:  2007-10       Impact factor: 4.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.